Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Louie, S.
Right arrow Articles by Yoon, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Louie, S.
Right arrow Articles by Yoon, H
American Journal of Health-System Pharmacy, Vol 60, Issue 4, 346-355
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Biological response modifiers in the management of rheumatoid arthritis

SG Louie, B Park, and H Yoon


The management of rheumatoid arthritis (RA) with biological response modifiers (BRMs) is reviewed. RA, an autoimmune disorder affecting 1-2% of the world's population, is characterized by inflammation of synovial tissues, joint swelling, stiffness, and pain that may progress to joint erosion. There is strong evidence that inflammatory mediators, such as tissue necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1), play a critical role in the pathogenesis of this disorder. IL-1-receptor antagonist (IL-1Ra) is produced in healthy subjects and helps to protect against the adverse effects associated with IL-1 overexpression. Administration of IL-1Ra or similar agents may reduce the effects of IL-1 and ameliorate inflammatory conditions. Traditional treatment of RA has been based on symptomatic management with non-steroidal antiinflammatory drugs, disease-modifying antirheumatic drugs, and corticosteroids, each of which has substantial drawbacks in terms of effectiveness or adverse effects. Newer therapeutic strategies for blocking the biological effects of inflammatory cytokines include antibodies directed against TNF (e.g., infliximab), soluble receptors (e.g., etanercept) and receptor antagonists to IL-1 (anakinra) [corrected]. Clinical trials indicate that these BRMs may be more effective than traditional agents because they are able to alter joint remodeling in addition to attenuating symptoms. Anti-TNF therapies may be associated with increased risk for infections, sepsis, tuberculosis reactivation, demyelination disorders, and blood dyscrasias; anakinra appears to be safer. Combination therapy with BRMs may be more appropriate for RA than monotherapy. The role of BRMs in the treatment of RA will evolve as investigators learn more about the drugs and the disorder.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
A. Sebba
Tocilizumab: The first interleukin-6-receptor inhibitor
Am. J. Health Syst. Pharm., August 1, 2008; 65(15): 1413 - 1418.
[Abstract] [Full Text] [PDF]

Home page
 Evid Based Complement Alternat MedHome page
J.-M. Chang, C.-M. Cheng, L.-M. Hung, Y.-S. Chung, and R.-Y. Wu
Potential Use of Plectranthus amboinicus in the Treatment of Rheumatoid Arthritis
Evid. Based Complement. Altern. Med., November 23, 2007; (2007) nem168v1.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
Robin Goodfellow (42-6)
Rheumatology, June 1, 2003; 42(6): 813 - 813.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.